Posted from: Tuesday, August 04, 2015 - 10:32 AM - Present

Safety Data Shows Increased Risk of Cardiovascular Events with NSAIDS

July 9, 2015 – The U.S. Food and Drug Administration (FDA)’s review of observational studies consisting of a combined clinical analysis and scientific observations resulted in the strengthening of its warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) increase the risk of heart attacks and strokes.

The FDA required updates to labels of all prescription NSAIDS and it requested that over- the- counter non-aspirin NSAIDs reflect these changes on their labels and drug fact sections, as well. NSAIDs such as naproxen, ibuprofen, diclofenac, and celecoxib will be required to include recommendations from the FDA advisory committee and safety review detailing heart attack and stroke risks associated with NSAIDs in their prescription labels.

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Friday, May 19, 2017 - 04:43 AM.